目的 探討降脂通便膠囊聯(lián)合普伐他汀鈉片治療高脂血癥的臨床療效。方法 選取2017年2月—2018年2月在邯鄲市第二醫(yī)院進行治療的94例高脂血癥患者作為研究對象，根據(jù)用藥的差別將患者分為對照組（47例）和治療組（47例）。對照組口服普伐他汀鈉片，20 mg/次，1次/d；治療組在對照組治療的基礎上口服降脂通便膠囊，2.0 g/次，2次/d。兩組均連續(xù)治療2個月。觀察兩組患者的臨床療效，比較兩組患者治療前后的血脂水平、炎性指標和肥胖指標水平。結果 治療后，對照組總有效率為80.85%，顯著低于治療組的97.87%，兩組比較差異具有統(tǒng)計學意義（P<0.05）。治療后，兩組患者膽固醇（TC）、三酰甘油（TG）、低密度脂蛋白膽固醇（LDL-C）水平均明顯降低，高密度脂蛋白膽固醇（HDL-C）水平明顯增高，同組治療前后比較差異具有統(tǒng)計學意義（P<0.05）；且治療組血脂水平顯著優(yōu)于對照組，兩組比較差異具有統(tǒng)計學意義（P<0.05）。治療后兩組血清超敏C反應蛋白（hs-CRP）、白細胞介素-1β（IL-1β）、干擾素-γ（IFN-γ）、腫瘤壞死因子-α（TNF-α）水平均顯著降低，同組治療前后比較差異具有統(tǒng)計學意義（P<0.05）；且治療組炎性指標水平顯著低于對照組，兩組比較差異具有統(tǒng)計學意義（P<0.05）。治療后，兩組體質量（W）、肥胖度（A）、體質量指數(shù)（BMI）、體脂率（F）均明顯降低，同組治療前后比較差異具有統(tǒng)計學意義（P<0.05）；且治療組肥胖指標水平顯著低于對照組，兩組比較差異具有統(tǒng)計學意義（P<0.05）。結論 降脂通便膠囊聯(lián)合普伐他汀鈉片治療高脂血癥可有效降低患者血脂和血清炎性因子水平，降低肥胖指標，具有較好的臨床推廣應用價值。

Objective To investigate the clinical efficacy of Jiangzhi Tongbian Capsules combined with Pravastatin Sodium Tablets in treatment of hyperlipidemia. Methods Patients (94 cases) with hyperlipidemia in Handan Second Hospital from February 2017 to February 2018 were randomly divided into control group (47 cases) and treatment group (47 cases), according to the difference of medication. Patients in the control group were po administered with Pravastatin Sodium Tablets, 20 mg/time, once daily. Patients in the treatment group were po administered with Jiangzhi Tongbian Capsules on the basis of the control group, 2.0 g/time, twice daily. Patients in two groups were treated for 2 months. After treatment, the clinical efficacy was evaluated, and the blood lipid, inflammatory markers, and obesity indexes levels in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control group was 80.85%, which was significantly lower than 97.87% in the treatment group, and there were differences between two groups (P<0.05). After treatment, the TC, TG, IL-4, and LDL-C levels in two groups were significantly decreased, but HDL-C level were increased, and the difference was statistically significant in the same group (P<0.05), and blood lipid levels in the treatment group were significantly better than those in the control group, with significant difference between two groups (P<0.05). After treatment, hs-CRP, IL-1β, IFN-γ, and TNF-α level in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And inflammatory markers in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). After treatment, W, A, BMI, and F levels in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And obesity indexes levels in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). Conclusion Jiangzhi Tongbian Capsules combined with Pravastatin Sodium Tablets in treatment of hyperlipidemia can effectively reduce the levels of blood lipid and serum inflammatory factors, and reduce obesity indexes, which has a certain clinical application value.

河北省衛(wèi)生廳科技計劃項目（20181661）